Once again RESPIRI another announce on progress in the US. This...

Once again RESPIRI another announce on progress in the US. This what ADR should be announcing.

What are NED George Barans' Monaghan Medical ( ADRs partner for two years) and the other announced partners and the VP Commercial doing in the US market ?

With the latest raise thats more than $30m in the last 18 months and nothing to show for it in terms of commercial success in the US. Why ?


18th November 2022
ASX ANNOUNCEMENT ASX: RSH
ASX Market Announcements Platform
Sydney NSW
wheezo® REMOTE PATIENT MONITORING (RPM) PILOT PROGRAM SELECTED BY MINNESOTA
LUNG CENTER A PREEMINENT PULMONARY CENTER OF EXCELLENCE IN THE USA.

Highlights:
• wheezo® and Access Telehealth RPM solutions has been selected for a pilot program to help manage
patients suffering from asthma and Chronic Obstructive Pulmonary Disease (COPD) that are cared for by
Minnesota Lung Center (MLC).
• Remote Patient Monitoring (RPM) solutions delivered through Access Telehealth will include a full-service
premium model that includes patient engagement using their cloud-based platform, Remotli. This pilot
program initially involves 20 patients and will be conducted over three months to ensure seamless integration
into MLC’s systems and processes.
• With 9 pulmonologists, 6 mid-level healthcare workers, including nurses, respiratory therapists and medical
assistants, and an extensive referral network, MLC is one of the largest private pulmonary practices in the
Midwest providing care and other related respiratory healthcare services to thousands of patients. MLC also
has a robust clinical research program.
Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health
management is pleased to announce that Minnesota Lung Center has chosen the wheezo® and RPM program for
a pilot program to help manage patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma. The
program was secured with our RPM partner Access Telehealth and will provide a full RPM solution that includes the
Remotli platform, patient engagement and remote monitoring under the supervision of MLC. Initially a pilot program
involving 20 patients will be conducted with Wheezo® over a 3-month period to ensure that the RPM program
seamlessly integrates into MLC systems and workflow.
RPM CPT reimbursement codes from this program will be processed through Centers for Medicare and Medicaid
Services (CMS) and private insurers. On the successful completion of the pilot program, that includes integration
and successful reimbursement, along with clinical benchmarks, it is anticipated that the wheezo® RPM program will
be rolled out more broadly for MLC patients.
Minnesota Lung Center (MLC) was established in 1974 to provide comprehensive specialty care for people with
respiratory health needs. MLC is committed to, and renowned for, high quality and compassionate care. They
specialize in the treatment of patients with lung diseases and offer patients a wide variety of diagnostic services.
MLC services are provided by 9 pulmonary physicians and other dedicated support staff including nurse
practitioners, physician assistants, registered nurses, and respiratory therapists.
Respiri Limited │ ABN 98 009 234 173 │ Suite 1, Level 9, 432 St Kida Road, MELBOURE VIC 3004 │
Page | 2
This is the first time that MLC will provide such a program that focuses on remote respiratory disease monitoring
using the novel wheezo® device to track and monitor patient physiologic data between clinical visits and after acute
care.